RT Journal Article
SR Electronic
T1 Leukemogenesis in Acute Lymphoblastic Leukemia through the Lens of Developmental Dynamics of Lymphoid Progenitor Cells: a systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.14.24310322
DO 10.1101/2024.07.14.24310322
A1 Shafi, Ovais
A1 Rajpar, Rahimeen
A1 Kanwal, Finza
A1 Waqas, Muhammad
A1 Khan, Osama Jawed
A1 Raveena,
A1 Kumar, Ankash
A1 Jabbar, Abdul
A1 Madhwani, Manwar
YR 2024
UL http://medrxiv.org/content/early/2024/07/14/2024.07.14.24310322.abstract
AB Objective The objective of this study is to investigate how lymphoid progenitor mechanisms contribute to the leukemogenesis in Acute Lymphoblastic Leukemia.Background Acute Lymphoblastic Leukemia (ALL), the leading childhood cancer, remains challenging despite treatment advances. ALL originates from aberrant clonal expansion of immature lymphoid progenitor cells (LPCs) due to genetic abnormalities. This study looks into LPC genetic dysregulations, aiming to identify therapeutic targets and enhance prognostic stratification. Understanding ALL pathogenesis not only improves outcomes but also informs broader cancer research, offering potential insights for hematologic malignancies and oncogenesis, promising advancements in clinical practice.Methods Databases, including PubMed, MEDLINE, Google Scholar, and open access/subscription-based journals were searched for published articles without any date restrictions, to investigate leukemogenesis in acute lymphoblastic leukemia and the impact of down syndrome through the developmental regulators of lymphoid progenitor cells. Based on the criteria mentioned in the methods section, studies were systematically reviewed to investigate ALL leukemogenesis. This study adheres to relevant PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses).Results Acute Lymphoblastic Leukemia (ALL) development is marked by dysregulations in key factors governing Lymphoid Progenitor Cells (LPCs) proliferation and differentiation. Dysregulations include upregulation of transcription factors Ikaros and PU.1, along with heightened expression of surface markers CD34 and CD38. Increased levels of signaling molecules IL-7, SCF, and FLT3 Ligand drive LPC proliferation, while alterations in epigenetic modifiers DNMTs, HDACs, and HATs further contribute to uncontrolled cell division. Dysregulated transcription factors Ikaros, PU.1, E2A (TCF3), EBF1, and Notch1 disrupt LPC differentiation pathways, alongside aberrant expression of surface markers CD10, CD7, and CD45RA. Dysregulated signaling through IL-7 and the Notch pathway, along with epigenetic modifications mediated by DNMTs, HDACs, and HATs, collectively create a conducive landscape for ALL development.Conclusion This study into the origins of ALL investigates the roles of transcription factors, surface markers, signaling molecules, and epigenetic modifiers in LPC proliferation and differentiation. Dysregulation of these components, often due to mutations in genes like GATA1, CRLF2, JAK2, and RAS, disrupts normal hematopoietic development and leads to leukemic transformation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementI declare that there was not any source of funding for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data generated or analyzed during this study are included in this article.NF-κBNuclear Factor-kappa BALLAcute Lymphoblastic LeukemiaLPCsLymphoid Progenitor CellsPU.1Purine-rich Box-1E2A (TCF3)Transcription Factor 3EBF1Early B-cell Factor 1SCFStem Cell FactorFLT3Fms-like Tyrosine Kinase 3IL-7Interleukin-7IkarosIKAROS family zinc finger 1CD34Cluster of Differentiation 34CD38Cluster of Differentiation 38CD10Cluster of Differentiation 10CD7Cluster of Differentiation 7CD45RACluster of Differentiation 45RANotch1Neurogenic locus notch homolog protein 1CRLF2Cytokine Receptor-like Factor 2JAK2Janus Kinase 2RASRat Sarcoma Virus Oncogene